Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant bevacizumab in triple-negative breast cancer
2007-001128-11Phase 3Completed
- Sponsor
- Roche
- Start
- Aug 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bevacizumab in triple-negative breast cancer (TNBC) and breast cancer (2 arms), sponsored by Roche. Primary endpoint: Invasive Disease-Free Survival (IDFS). Started Aug 2007; status: completed.
02
Drugs
bevacizumab
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on 2007-001128-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001128-11.